Back
 AJMB  Vol.8 No.2 , April 2018
Polymorphism of Human Organic Cationic Transporter1 (C480G) in Egyptian Chronic Myeloid Leukemia Patients on Imatinib
Abstract: Background: Human organic cationic transporter1 (Hoct1) is a plasma membrane transporter responsible for the main influx of Imatinib into chronic myeloid leukemia (CML) cells. Single nucleotide polymorphisms (SNPs) in the gene coding for hOCT1 are important factors causing Imatinib resistance. We investigated the frequency of hOCT1 SNP C480G among Egyptian CML patients and its relation to early molecular response as an indicator of treatment outcome. Materials and Methods: Two groups of CML patients were included in this study. Group I consisted of 25 patients responding to Imatinib treatment (Imatinib responsive) and group II consisted of 25 patients resistant to Imatinib (Imatinib resistant). Response criteria were assessed according to the NCCN (National Comprehensive Cancer Network) guidelines 2017. Twenty healthy controls of matched age and sex were also included (group III). For all patients, we studied hOCT1 C480G at initial presentation using Taqman drug metabolism genotyping as well as BCR-ABL percent at diagnosis and after 3 months interval. Results: hOCT1 C480G was present in 32% of studied CML patients. CC (wild) was detected in 68% of group I and 64% of group II. CG (mutant heterozygous) was present in 28% of group I and 36% of group II while GG (mutant homozygous) was detected in only one case in group I. CG was also detected in 15% of control subjects There was no significant difference between hOCT1 C480G polymorphism and Early Molecular Response (χ2 = 0.089, p = 0.765). Conclusions: hOCT1 C480G polymorphism has no association with Imatinib resistance in Egyptian population. However, further studies on a larger number of patients are still needed to confirm this finding.
Cite this paper: Hamed, N. , Neanea, H. , Ghanem, A. , Elgammal, M. and Samir, Y. (2018) Polymorphism of Human Organic Cationic Transporter1 (C480G) in Egyptian Chronic Myeloid Leukemia Patients on Imatinib. American Journal of Molecular Biology, 8, 83-91. doi: 10.4236/ajmb.2018.82007.
References

[1]   Jabbour, E. and Kantarjian, H. (2016) Chronic Myeloid Leukemia: 2016 Update on Diagnosis, Therapy, and Monitoring. American Journal of Hematology, 91, 252-265.
https://doi.org/10.1002/ajh.24275

[2]   Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30.
https://doi.org/10.3322/caac.21387

[3]   Yeung, D.T. and Hughes, T.P. (2016) Chronic Myeloid Leukemia. In: Hoffbrand, A.V., Higgs, D.R., Keeleg, M.M. and Mehta, A.B., Eds., Postgraduate Hematology, 7th Edition, John Wiley & Sons Ltd., Wiley Blackwell, 419-437.

[4]   Iqbal, N. and Iqbal, N. (2014) Imatinib: A Breakthrough of Targeted Therapy in Cancer. Chemotherapy Research and Practice, 2014, Article ID: 357027.
https://doi.org/10.1155/2014/357027

[5]   Jabbour, E., Kantarjian, H. and Cortes, J. (2015) Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. Clinical Lymphoma, Myeloma and Leukemia, 15, 323-334.
https://doi.org/10.1016/j.clml.2015.03.006

[6]   Cortes, J.E., Saglio, G., Kantarjian, H.M., Baccarani, M., Mayer, J., Boqué, C., et al. (2016) Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology, 34, 2333-2340.
https://doi.org/10.1200/JCO.2015.64.8899

[7]   Hochhaus, A., Saglio, G., Hughes, T.P., Larson, R.A., Kim, D.W., Issaragrisil, S., et al. (2016) Long-Term Benefits and Risks of Frontline Nilotinib vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-Year Update of the Randomized ENESTnd Trial. Leukemia, 30, 1044-1054.
https://doi.org/10.1038/leu.2016.5

[8]   Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., et al. (2013) Combining BCR-ABL1 Transcript Levels at 3 and 6 Months in Chronic Myeloid Leukemia: Implications for Early Intervention Strategies. Blood, 121, 2739.
https://doi.org/10.1182/blood-2012-11-466037

[9]   Khorashad, J.S., Kelley, T.W., Szankasi, P., Mason, C.C., Soverini, S., Adrian, L.T., et al. (2012) BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitor-Resistant CML: Frequency and Clonal Relationships. Blood, 121, 489-498.
https://doi.org/10.1182/blood-2012-05-431379

[10]   Thomas, J. (2004) Active Transport of Imatinib into and Out of Cells: Implications for Drug Resistance. Blood, 104, 3739-3745.
https://doi.org/10.1182/blood-2003-12-4276

[11]   Arimany-Nardi, C., Minuesa, G., Keller, T., Erkizia, I., Koepsell, H., Martinez-Picado, J., et al. (2016) Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Frontiers in Pharmacology, 7, 175.
https://doi.org/10.3389/fphar.2016.00175

[12]   Marin, J.J.G. (2012) Plasma Membrane Transporters in Modern Liver Pharmacology. Scientifica, 2012, Article ID: 428139.
https://doi.org/10.6064/2012/428139

[13]   Arimany-Nardi, C., Koepsell, H. and Pastor-Anglada, M. (2015) Role of SLC22A1 Polymorphic Variants in Drug Disposition, Therapeutic Responses, and Drug-Drug Interactions. The Pharmacogenomics Journal, 15, 473-487.
https://doi.org/10.1038/tpj.2015.78

[14]   Di Paolo, A., Polillo, M., Capecchi, M., Cervetti, G., Baratè, C., Angelini, S., et al. (2014) The c.480C > G Polymorphism of hOCT1 Influences Imatinib Clearance in Patients Affected by Chronic Myeloid Leukemia. The Pharmacogenomics Journal, 14, 328-335.
https://doi.org/10.1038/tpj.2014.7

[15]   Maffioli, M., Camós, M., Gaya, A., Hernández-Boluda, J.-C., álvarez-Larrán, A., Domingo, A., et al. (2011) Correlation between Genetic Polymorphisms of the hOCT1 and MDR1 Genes and the Response to Imatinib in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia. Leukemia Research, 35, 1014-1019.
https://doi.org/10.1016/j.leukres.2010.12.004

[16]   Vine, J., Cohen, S.B., Ruchlemer, R., Goldschmidt, N., Levin, M., Libster, D., et al. (2014) Polymorphisms in the Human Organic Cation Transporter and the Multidrug Resistance Gene: Correlation with Imatinib Levels and Clinical Course in Patients with Chronic Myeloid Leukemia. Leukemia & Lymphoma, 55, 2525-2531.
https://doi.org/10.3109/10428194.2014.893307

[17]   Watkins, D.B., Hughes, T.P. and White, D.L. (2015) OCT1 and Imatinib Transport in CML: Is It Clinically Relevant? Leukemia, 29, 1960-1969.

[18]   National Comprehensive Cancer Network (2018) Chronic Myeloid Leukemia.
https://www.nccn.org/professionals/physician_gls/PDF/cml.pdf

[19]   Foroni, L., Wilson, G., Gerrard, G., Mason, J., Grimwade, D., White, H.E., et al. (2011) Guidelines for the Measurement of BCR-ABL1 Transcripts in Chronic Myeloid Leukaemia. British Journal of Haematology, 153, 179-190.
https://doi.org/10.1111/j.1365-2141.2011.08603.x

[20]   Takahashi, N., Miura, M., Scott, S.A., Kagaya, H., Kameoka, Y., Tagawa, H., et al. (2010) Influence of CYP3A5 and Drug Transporter Polymorphisms on Imatinib Trough Concentration and Clinical Response among Patients with Chronic Phase Chronic Myeloid Leukemia. Journal of Human Genetics, 55, 731-737.
https://doi.org/10.1038/jhg.2010.98

[21]   de Lima, L.T., Vivona, D., Bueno, C.T., Hirata, R.D.C., Hirata, M.H., Luchessi, A.D., et al. (2014) Reduced ABCG2 and Increased SLC22A1 mRNA Expression Are Associated with Imatinib Response in Chronic Myeloid Leukemia. Medical Oncology, 31, 851.
https://doi.org/10.1007/s12032-014-0851-5

[22]   Koren-Michowitz, M., Buzaglo, Z., Ribakovsky, E., Schwarz, M., Pessach, I., Shimoni, A., et al. (2013) OCT1 Genetic Variants Are Associated with Long Term Outcomes in Imatinib Treated Chronic Myeloid Leukemia Patients. European Journal of Hematology, 92, 283-288.
https://doi.org/10.1111/ejh.12235

[23]   Ankathil, R., Siti Maziras, M., Ahmad Aizat, A.A., Au Zian, A. and Azlan, H. (2014) OP0025 Genetic Association of C480G Polymorphism of SLC22A1 with Clinical Resistance to Imatinib Mesylate in Malaysian Patients with Chronic Myeloid Leukaemia. European Journal of Cancer, 50, e9.

[24]   Kim, D.H., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., et al. (2009) Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. Clinical Cancer Research, 15, 4750.
https://doi.org/10.1158/1078-0432.CCR-09-0145

[25]   Chhikara, S., Sazawal, S., Seth, T., Chaubey, R., Singh, K., Sharma, R., et al. (2017) Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients. Asian Pacific Journal of Cancer Prevention, 18, 2043-2048.

 
 
Top